Northeast Florida Medicine
Vol. 66, No. 2 2015
35
Pediatric Oncology
800mCi. Long-term stable persistent disease is very possible
and survival over 90-95 percent, despite the extent of disease
at presentation.
Conclusion
DTC in childhood presents with both a high incidence of
nodal and distant metastases. Following multimodality treat-
ment, 35-40percentwill experience recurrence (most in thyroid
bed or cervical nodes), but overall survival is in excess of 90-95
percent.
1
Treatment decisions should be based on risk factors,
extent of disease at presentation, need for close multimodality
post-therapy testing and response to treatment. Complications
of treatment include hypoparathyroidism, RLN injury, local
and systemic toxicities due to RAI therapy and the induction
of SMNs and are important considerations when determining
surgical approach and total accumulative RAI dose given.
Successful treatment of MTC hinges on identifying those at
risk and performing a prophylactic total thyroidectomy prior
to disease occurrence.
v
References
1. Rapkin L, Pashankar F. Management of thyroid carci-
noma in children and young adults.
J Pediatr Hematol
Oncol.
2012;34:S39-S46.
2. Dinauer CA, Breuer C, Rivkees SA. Differentiated
thyroid cancer in children: diagnosis and management.
Curr Opin Oncol.
2008;20:59-65.
3. Vasko V, Bauer AJ, Tuttle RM, “et al”. Papillary and
follicular thyroid cancers in children.
Endocr Dev.
2997;10:140-172.
4. Thompson GB, Hay ID. Current strategies for
surgical management and adjuvant treatment of
childhood papillary thyroid carcinoma.
World J Surg.
2004;28:1187-1198.
5. Yamashita S, Saenko V. Mechanisms of disease: Mo-
lecular genetics of childhood thyroid cancers.
Nature
Clinical Practice – Endocrinology and Metabolism.
2007;3:422-429.
6. La Quaglia M, Telander RL. Differentiated and medul-
lary thyroid cancer in childhood and adolescence.
J Ped
Surg.
2007;6:42-49.
7. Maule M, Scelo G, Pastore G, “et al”. Risk of second
malignant neoplasms after childhood leukemia and
lymphoma: An international study.
J Natl Cancer Inst.
2007;99:790-800.
8. Davies SM. Subsequent malignant neoplasms in
survivors of childhood cancer: Childhood cancer
survivor study (CCSS) studies.
Pediatr Blood Cancer.
2007;48:727-730.
9. Papendieck P, Gruneiro-Papendieck L, Venara M, “et
al”. Differentiated thyroid cancinoma: presentation
and follow-up in children and adolescents.
J Pediatr
Endocr Met.
2011;24:743-748.
10. Gingalewski CA, Newman KD. Seminars: Controver-
sies in the management of pediatric thyroid malignancy.
J Surg Oncol.
2006;94:748-752.
11. Dinauer C, Francis GL. Thyroid cancer in children.
Endocrinol Metab Clin N Am
207;36;779-806.
12. James EM, Charboneau JW, Hay ID. The thyroid. In:
Rumack CM, Wilson SR, Charborneau JW, editors.
Diagnostic ultrasound, vol 1 St. Louis (MO):
Mosby
Year Book
1991;507-523.
13. Stulak JM, Grant CS, Farley DR, “et al”. Value of
preoperative ultrasonography in the surgical man-
agement of initial and reoperative papillary thyroid
cancer.
Arch Surg.
2006;141:489-496.
14. Kuo SF, Chao TC, Hsueh C, “et al”. Prognosis and
risk stratification in young papillary thyroid carcinoma
patients.
Endocrine J.
2008;55:269-275.
15. Robie DK, Welch Dinauer C, Tuttle RM, “et al”. The
impact of initial surgical management on outcome in
young patients with differentiated thyroid cancer.
J Ped
Surg
1998;33:1134-1140.
16. Wada N, Sugino K, Mimura T, “et al”. Treatment
strategy of papillary thyroid carcinoma in children and
adolescents: Clinical significance of the initial nodal
manifestation.
Ann Surg Oncol.
2009;16:3442-3449.
17. Powers PA, Dinauer CA, Tuttle RM, “et al”. The
MACIS score predicts the clinical course of papillary
thyroid carcinoma in children and adolescents.
J Ped
Endocr Metab.
2004;17:339-343.
18. Spinelli C, Bertocchini A, Antonelli A, “et al”. Surgical
therapy of the thyroid papillary carcinoma in children:
Experience with 56 patients <= 16 years old.
J Ped
Surg.
2004;39:1500-1505.
19. 19 - Demidchik YE, Demidchik EP, Reiners C, “et
al”. Comprehensive clinical assessment of 740 cases of
surgically treated thyroid cancer in children of Belarus.
Ann Surg.
2006;243:525-532.
20. Park S, Jeong JS, Ryu HR, “et al”. Differentiated
thyroid carcinoma of children and adolescents: 27-year
experience in the Yonsie university health system.
J
Korean Med.
2013;28:693-699.
21. Handkiewicz-Junak D, Wloch J, Roskosz J, “et al”. To-
tal thyroidectomy and adjuvant radioiodine treatment
independently decrease locoregional recurrence risk in
childhood and adolescent differentiated thyroid cancer.
J Nucl Med.
2007;48:879-888.
